TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02775786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRIs with and without intravenous contrast (up to 2)
Description: Participants will undergo up to two MRIs with and without intravenous contrast. The first MRI will be performed using an extracellular contrast agent and the second 1-14 days later, with a macromolecular contrast agent. If patient cannot undergo the second MRI for any reason eg. not enough time before surgery, one MRI with either contrast agent will still be used for analysis.
Study: NCT04004741

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: The purpose of this research is to investigate the effect of osteopathic manipulative treatment (OMT) focused on somatic dysfunctions commonly associated with arrhythmias on the amount of quantifiable arrhythmias as recorded on a diagnostic device.~It is known that OMT has a stabilizing effect on the autonomic nervous system, which plays a key role in regulating heart rate and blood pressure. This increases parasympathetic tone and decreases sympathetic tone, which generally stabilizes the heart with an antiarrhythmic effect.~Previous work has been done showing that osteopathic treatment is a beneficial adjunctive therapy for paroxysmal atrial fibrillation and decreased symptoms, though has not been proven to be helpful for patients with heart failure.~While the effect of OMT on the neurology has been studied, we would like to further research the effect OMT specifically has on arrhythmias using more quantifiable data from implanted devices.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Light Touch Therapy
Description: The physician will contact various areas of the body for 120 seconds each to expose the subject to a similar environment as the interventional group, without stimulating the autonomic nervous system.
Study: NCT02081677

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ACUVUE 2
Description: worn in a daily wear modality; lenses will be replaced after 2 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype E1
Description: worn in a daily wear modality; lenses will be replaced after 2 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype E2
Description: worn in a daily wear modality; lenses will be replaced after 2 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype E3
Description: worn in a daily wear modality; lenses will be replaced after 2 weeks
Study: NCT00648063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole Tablets 2.5 mg
Description: 2.5mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femara® Tablets 2.5 mg
Description: 2.5mg, single dose fasting
Study: NCT03939689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-131-1095
Description: I-131-1095 will be administered intravenously at 100 mCi for the initial therapeutic dose, and up to 3 additional dose(s) at 75 mCi or 100 mCi each, administered at least 8 weeks apart as determined by dosimetry evaluation and occurrence of dose-limiting events.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide will be given orally once daily as prescribed by the physician as standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide will be given orally once daily as prescribed by the physician as standard of care.
Study: NCT05515965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: The mechanical correction method of taping to the Kinesiotape group was used. In rheumatoid hand patients, due to the presence of a deformity called hitchhiker's finger, the thumb is taped with 50-75% tension to create a pulling force in the direction of flexion and abduction. The application was performed with the patient in a sitting position with his arm supported by a pillow from the elbow. Evaluation parameters were evaluated before and 1 hour after the application, and the acute effect was examined. Both the dominant and nondominant hands of the patients were taped and the differences between the two hands were also examined.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham application was applied to both dominant and nondominant hands in Control Group patients. Sham taping is the bonding of I tape to the 1st finger without tension and does not contain any features. Evaluation parameters were evaluated before and 1 hour after the application, and the acute effect was examined. Both the dominant and nondominant hands of the patients were taped and the differences between the two hands were also examined.
Study: NCT02405078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Given standard salvage chemotherapy
Study: NCT02294227

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to secukinumab was also available in 1.0 mL liquid formulation in prefilled syringe to match the active drug.
Study: NCT02679352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMR Stemless
Description: Total anatomic or reverse shoulder arthroplasty
Study: NCT01656382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABLC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABLC
Study: NCT00126373

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Wellbutrin (bupropion)
Description: bupropion 150mg-300mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wellbutrin (bupropion)
Description: bupropion 150mg-300mg daily
Study: NCT02175251

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high frequency (20Hz)
Description: 10 session in 5 days with high frequency (20 Hz)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low frequency (1Hz)
Description: 10 session in 5 days with low frequency (1Hz)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: 10 session in 5 days with sham-controlled
Study: NCT04927182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Exercise Training (Age Group 1; Young adult 17 -30 years)
Description: Supervised Moderate exercise training will be given. This protocol consisted of 3 types of exercises. This includes walking/jogging/running for 23 minutes cycling for 23 minutes and stepping for 5 minutes. The protocol will be performed in 50 minutes sessions thrice a week.
Study: NCT02405078

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG-PET/CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET/CT scan
Study: NCT03712696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIGNICAP™
Description: Scalp cooling to prevent chemotherapy-induced alopecia
Study: NCT00265993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin
Description: * All patients will be treated with enoxaparin 1.5 mg/kg, once a day, subcutaneously for up to 10 days.~* Long-term oral anticoagulation will be started in all patients after 24 hours of initiation of enoxaparin treatment and continued at least for 3 months.
Study: NCT03384615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion-Focused Therapy
Description: CFT for PGD symptoms in the present project is inspired by two well-established CFT treatment manuals. The first is used for treatment of PTSD (Lee \& James, 2011) and the other for treatment of anger (Kolt, 2011). The manual for CFT for PGD adopts both structure and techniques from these into an 8-week, group-based program with weekly 2 1/4-hour sessions. Each session contains elements of psychoeducation on uncomplicated and prolonged grief reactions, identifying unhelpful strategies for self-protection and facilitating use of more helpful strategies, and training an open and compassionate management of grief-related distress through CFT exercises. Between the sessions the participant will train the exercises introduced at the previous session.
Study: NCT04927182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Exercise Training (Age Group 2; 31 to 45 years)
Description: Supervised Moderate exercise training will be given. This protocol consisted of 3 types of exercises. This includes walking/jogging/running for 23 minutes cycling for 23 minutes and stepping for 5 minutes. The protocol will be performed in 50 minutes sessions thrice a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Exercise Training (Age Group 3; Above 45 years)
Description: Supervised Moderate exercise training will be given. This protocol consisted of 3 types of exercises. This includes walking/jogging/running for 23 minutes cycling for 23 minutes and stepping for 5 minutes. The protocol will be performed in 50 minutes sessions thrice a week.
Study: NCT04703231

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of macular thickness, corneal thickness and lens opacities
Description: The incidence of macular thickness, Corneal thickness, intraocular pressure and lens opacities will be investigated by an ophthalmologist.

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of macular thickness, corneal thickness and lens opacities
Description: The incidence of macular thickness, Corneal thickness, intraocular pressure and lens opacities will be investigated by an ophthalmologist.
Study: NCT02701140

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary stenting
Description: Within 1h after the first PCI, patients will be randomized to either ticagrelor or clopidogrel.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary stenting
Description: Within 1h after the first PCI, patients will be randomized to either ticagrelor or clopidogrel.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intracoronary ECG recording
Description: Measurement of ST segment elevation using intracoronary ECG recording

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intracoronary ECG recording
Description: Measurement of ST segment elevation using intracoronary ECG recording

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Flow reserve
Description: measured with an intracoronary pressure/temperature sensor-tipped guidewire

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Flow reserve
Description: measured with an intracoronary pressure/temperature sensor-tipped guidewire

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Index of Microcirculatory Resistance
Description: measured with an intracoronary pressure/temperature sensor-tipped guidewire

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Index of Microcirculatory Resistance
Description: measured with an intracoronary pressure/temperature sensor-tipped guidewire

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Flow Reserve
Description: measurement of Fractional Flow Reserve during hyperemic phase.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Flow Reserve
Description: measurement of Fractional Flow Reserve during hyperemic phase.
Study: NCT02927600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low GI Breakfast
Description: Intake of low GI breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High GI Breakfast
Description: Intake of high GI breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low GI Dinner
Description: Intake of Low GI dinner

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High GI Dinner
Description: Intake of high GI dinner
Study: NCT03453320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin solution
Description: Infusion rate and effects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin solution
Description: Infusion rate and effects
Study: NCT00038974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study: NCT01904123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAT3 Inhibitor WP1066
Description: Given PO
Study: NCT00475930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate (CHG) impregnated cloths
Description: self applied three times per week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comfort Bath cloths (placebo cloths)
Description: self applied three times weekly
Study: NCT00561054

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: CETUXIMAB
Description: 400 mg/m2 starting dose, 250 mg/m2 weekly dose
Study: NCT00824161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-109
Description: 14-day continuous central intravenous infusion at a dose of 2.0 mg/m2/day followed by a 7-day rest period.~Number of cycles: until unacceptable toxicity or disease progression requires discontinuation.
Study: NCT02084745

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Boston keratoprosthesis type 1
Description: The Boston KPro, purchased from Massachusetts Eye and Ear infirmary (Boston, MA), is implanted using the usual standard technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Boston keratoprosthesis type 1
Description: The Boston KPro, purchased from Massachusetts Eye and Ear infirmary (Boston, MA), is implanted using the usual standard technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glaucoma drainage device
Description: The GDD that will be used is the Ahmed implant (New World Medical, Rancho Cucamonga, CA). The Ahmed implant will be implanted using the standard technique either at the time of KPro surgery in group 1, or 6 months following KPro in group 2.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glaucoma drainage device
Description: The GDD that will be used is the Ahmed implant (New World Medical, Rancho Cucamonga, CA). The Ahmed implant will be implanted using the standard technique either at the time of KPro surgery in group 1, or 6 months following KPro in group 2.
Study: NCT03151096

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: one pill of Riboflavin will be taken orally with water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one pill of placebo will be taken orally with water
Study: NCT02892344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QMF149 150/80 μg
Description: QMF149 150/80 μg o.d via Concept1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MF 200 μg
Description: MF 200 μg o.d. via Twisthaler®
Study: NCT03520829

Intervention type: DEVICE
Intervention: Intuitive Plan
Description: dosimetric planning software
Study: NCT02553226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
Study: NCT01968200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: Naprilene 5 mg tablets; Dosage: 2.5 to 10 mg/12h Duration of treatment: up to end of follow up

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: Naprilene 5 mg tablets; Dosage: 2.5 to 10 mg/12h Duration of treatment: up to end of follow up
Study: NCT02611297

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cryoprobe
Study: NCT02628288

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Bifurcation PCI
Description: In one group, the coronary bifurcation lesion will be treated (Coronary bifurcation PCI) with the Axxess device + Absorb BVS. In the other group, the coronary bifurcation lesions will be treated(Coronary bifurcation PCI) by modified T stenting using Absorb BVS.
Study: NCT01398722

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive insulin therapy
Description: Titration of the IV insulin rate for glucose goal 110-150 mg/dL

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional insulin therapy
Description: Titration of the IV insulin rate for glucose goal 150-180 mg/dl
Study: NCT00491829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg qhs
Description: flibanserin 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg
Description: flibanserin 100mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01636960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIFN alfa-2b
Study: NCT03139110

Intervention type: BEHAVIORAL
Intervention: Presence of a mediator in the emergency departments
Description: The mediator tasks are :~* Be available to patients who can solicit him and respond to their requests for information, in particular on the organization of the emergency departments and on waiting times~* Have a proactive attitude towards patients showing nervousness signs~* Report patients expressing the will to leave the emergency departments before medical care~* Manage conflicts between patients / accompanying persons and emergency staff and also between patients.
Study: NCT04932668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feasibility and Impact of Home-based Electrical Stimulation Program
Description: Home-based NMES program on spastic leg. The NMES pre-programmed dosage (locked):~NMES waveform is biphasic PC, Frequency 50Hz, pulse width 400µs, ON:OFF 10s:20s and current amplitude: individual maximum tolerated to achieve ankle dorsiflexion.
Study: NCT04044274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOPstim
Description: IOPstim (IMEDOS, Jena, Germany) is a device exerting defined pressure to the sclera and hence increasing IOP.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suction Cup
Description: Suction Cup is a device exerting defined suction to the clear and hence increasing IOP
Study: NCT01542931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy
Description: Docetaxel (at a dose of 75mg/m2 of body surface area) was administered as a 2-hour intravenous infusion, followed by intravenous cisplatin (75 mg/m2), administered during a period of 2 to 3 hours. After completion of the cisplatin infusion, 5-Fu (750 mg/m2/day) was administered during a period at least 8 hours for 5 days. Induction chemotherapy was given every 3 weeks for 2 cycles, unless there was disease progression, unacceptable toxic effects, or withdrawal of consent by the patient.
Study: NCT00419666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol 3mcg/g
Description: Calcitriol 3mcg/g ointment applied twice daily for 56 weeks.
Study: NCT01538927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant
Description: Fibrin Sealant 4ml (Baxter Tisseel)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Suture
Description: Black silk 000
Study: NCT01248091

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nitroprusside Gel
Description: 10 cc nitroprusside gel

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: half of the subjects will receive nitroprusside gel for IUD insertion and the other half will receive a placebo gel.
Study: NCT03034304

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MASCT-I
Description: The final products of MASCT-I technology are dendritic cells (DC) and effector T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 2g/m2/d, intravenous drip for 30min. Administration is conducted for continuous 5 days. After 4 weeks, the above cycle is repeated for 6 continuous cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1 antibody
Description: 200 mg/every two weeks ,four weeks is a cycle. Subjects were treated with MASCT-I combined with PD1 antibody until disease progression, MASCT-I intolerance or study completion. If PD1 antibody intolerance occurs, MASCT-I therapy alone will continue. MASCT-I and PD1 antibody are adminnistered according to their respective drug cycle without interfering with each other.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: 60mg/m2, from the first day of each cycle, it is used for 1-2 days, intravenous drip. Repeat the above cycle after 4 weeks, no more than 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2, Intravenous drip for about 30 min, used on the first and eighth days of each cycle, and every 3-4 weeks as a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 70mg/m2, Use on the first day of each chemotherapy cycle, intravenous drip for 30-120 min, and every 3-4 weeks as a cycle;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 5mg/ml/min, Use it on the first day of each chemotherapy cycle, intravenous drip for 30 minutes, and every 3-4 weeks as a cycle
Study: NCT02318797

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Self-Directed Care
Description: Patient self-management toolkits, web portal with information on health conditions, personal health care use data, health tracking tools and wellness programs

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provider-Supported Integrated Care
Description: Registered nurse on staff at community mental health centers with access to patient-level physical health information to: 1) work with patients on coordinating their care, 2) enhance communication between providers and payer, and 3) provide patient wellness support and education
Study: NCT02778711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab
Description: anti-IL-17